Stephen B. Erickson, M.D., is primarily a clinician and teacher, though he has interests in clinical trials that test new treatments.
- Cystine kidney stones. Dr. Erickson was primary investigator on a trial that added Cystone, an herbal supplement, to conventional treatment. There was no benefit.
- Enteric oxaluria. Enteric oxaluria occurs after weight-loss surgery and other bowel surgery. Dr. Erickson participated in a trial that showed some efficacy of ingesting oxalate-eating bacteria.
- Calcium stones. Calcium stones often form because urine is too concentrated. Dr. Erickson is co-investigator in a trial of tolvaptan to see if it dilutes urine.
- AA amyloidosis. AA amyloidosis is a rare disease. Dr. Erickson is site investigator testing Kiacta, a new drug treatment.
- Glomerulonephritis. Membranous and IgA nephropathies are forms of glomerulonephritis that can destroy kidney function. Dr. Erickson is participating in trials of Rituxan to induce disease remission.
Significance to patient care
Kidney stones cause pain, emergency department visits, surgery and loss of work. Better treatment will save money and reduce disability.
Glomerulonephritis often leads to kidney failure. Better treatment will avoid dialysis and transplants.